Transmembrane activator and CAML interactor

From Wikipedia, the free encyclopedia
  (Redirected from TNFRSF13B)
Jump to: navigation, search
"TACI" redirects here. TACI may also refer to Total Anterior Circulation Infarct.
Tumor necrosis factor receptor superfamily, member 13B
Protein TNFRSF13B PDB 1xu1.png
PDB rendering based on 1xu1.
Available structures
PDB Ortholog search: PDBe, RCSB
External IDs OMIM604907 MGI1889411 HomoloGene49320 IUPHAR: 1885 GeneCards: TNFRSF13B Gene
RNA expression pattern
PBB GE TNFRSF13B 207641 at tn.png
More reference expression data
Species Human Mouse
Entrez 23495 57916
Ensembl ENSG00000240505 ENSMUSG00000010142
UniProt O14836 Q9ET35
RefSeq (mRNA) NM_012452 NM_021349
RefSeq (protein) NP_036584 NP_067324
Location (UCSC) Chr 17:
16.83 – 16.88 Mb
Chr 11:
61.13 – 61.15 Mb
PubMed search [1] [2]

Transmembrane activator and CAML interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) is a protein that in humans is encoded by the TNFRSF13B gene

TNFRSF13B is a transmembrane protein of the TNF receptor superfamily found predominantly on the surface of B cells, which are an important part of the immune system.[1] TACI recognizes three ligands: APRIL, BAFF and CAML.


TACI is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It was originally discovered because of its ability to interact with calcium-modulator and cyclophilin ligand (CAML). TACI was later found to play a crucial role in humoral immunity by interacting with two members of the TNF family: BAFF and APRIL. These proteins signal through TACI inducing activation of several transcription factors including NFAT, AP-1, and NF-kappa-B which then modulate cellular activities. Defects in the function of TACI can lead to immune system diseases.

TACI controls T cell-independent B cell antibody responses, isotype switching, and B cell homeostasis.

Clinical significance[edit]

TACI mutations are associated with immunodeficiency in humans, as a significant proportion of CVID patients have TACI mutations. People with this condition produce abnormally low amounts of antibodies, which are needed for protection against infections.

In humans, the gene encoding this protein is located within the Smith-Magenis syndrome region on chromosome 17.[1]


TNFRSF13B has been shown to interact with B-cell activating factor,[2][3] TRAF6,[3] TRAF5,[3] TNFSF13,[2] TRAF2[3] and CAMLG.[3][4]


  1. ^ a b "Entrez Gene: TNFRSF13B tumor necrosis factor receptor superfamily, member 13B". 
  2. ^ a b Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K et al. (Nov 2000). "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS". The Journal of Biological Chemistry 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646. 
  3. ^ a b c d e Xia XZ, Treanor J, Senaldi G, Khare SD, Boone T, Kelley M et al. (Jul 2000). "TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation". The Journal of Experimental Medicine 192 (1): 137–43. doi:10.1084/jem.192.1.137. PMC 1887716. PMID 10880535. 
  4. ^ von Bülow GU, Bram RJ (Oct 1997). "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily". Science 278 (5335): 138–41. doi:10.1126/science.278.5335.138. PMID 9311921. 

Further reading[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.